BPA Call 36E79726A0012-36C24526N0787
Award Date 7/31/26
Potential Completion Date 8/4/26
Potential Value $38K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Not listed Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Brooks, KY 40109, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Veterans Integrated Service Network 5 issued a BPA call to Takeda Pharmaceuticals America, Inc. on July 28, 2026, with a ceiling value of $34,605.34 under a Blanket Purchase Agreement for pharmaceutical supply. Ultimate completion is July 29, 2026. Place of performance is Carrollton, Texas. The call procures ICLUSIG (ponatinib) tablets, a specialty oncology pharmaceutical for chronic myeloid leukemia and acute lymphoblastic leukemia, under firm fixed price terms. This represents a routine...
- On January 15, 2026, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a delivery order valued at $38,097.52 to Takeda Pharmaceuticals America Inc. for TAKHZYRO 150 MG, a specialized pharmaceutical product used to treat rare genetic disorders. This firm fixed-price delivery order, with an ultimate completion date of January 20, 2026, represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and does not utilize a set-aside...
- On November 7, 2025, the Department of Veterans Affairs, Veterans Integrated Service Network 5, awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of November 13, 2025. The award was made without a...
- On December 16, 2025, the Department of Veterans Affairs Veterans Integrated Service Network 5 awarded a firm fixed-price delivery order valued at $36,984.28 to Takeda Pharmaceuticals America Inc. for the supply of TAKHZYRO 150 mg, a specialized pharmaceutical treatment for hereditary angioedema. This delivery order represents a child contract under the GSA Pharmaceuticals and Drugs Schedule (FSS-61-IB) and carries an ultimate completion date of December 18, 2025. The contract was awarded...
- The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 awarded Takeda Pharmaceuticals America Inc. a $36,890.40 firm fixed price delivery order for TAKHZYRO under the company's Pharmaceuticals and Drugs General Services Administration schedule contract. TAKHZYRO will be delivered to facilities in Lexington, Massachusetts by June 7, 2024 to support treatment of hereditary angioedema. No set-aside was applied given the specialized nature of the...
- Takeda Pharmaceuticals America Inc. was awarded a $36,984.28 firm fixed-price delivery order for TAKHZYRO 150 MG, a specialized pharmaceutical treatment for hereditary angioedema. The contract, issued on October 16, 2025, with an ultimate completion date of October 17, 2025, is a child order under Takeda's broader Blanket Purchase Agreement with the VA National Acquisition Center valued at $131.04 million. The award was issued without a set-aside designation, reflecting the specialized and...
- The Department of Veterans Affairs Veterans Health Administration awarded Takeda Pharmaceuticals America Inc. a $36,101.68 firm fixed price delivery order for two packages of TAKHZYRO 150MG/ML prefilled syringes. Takeda Pharmaceuticals America Inc. will deliver the packages of the hereditary angioedema preventative medication to a location in Lexington, Massachusetts by November 1, 2023 to support VHA programs. The award was issued against Takeda Pharmaceutical Company Limited's...
- This firm fixed price delivery order for $36,890.40 was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 9 to Takeda Pharmaceuticals America Inc. against the company's Pharmaceuticals and Drugs GSA Schedule contract. The order is for two 150 mg/ml, 2ml injectable syringes of TAKHZRYO to treat hereditary angioedema. Performance will take place in Lexington, Massachusetts by February 6, 2024. No set-aside was applied given the...
- The Department of Veterans Affairs (VA) Veterans Health Administration awarded a firm fixed-price delivery order to Takeda Pharmaceuticals America Inc. under the company's Pharmaceuticals and Drugs GSA Schedule contract. The $36,890.40 order is for the specialty pharmaceutical product TAKHZYRO 150MG ML SYRINGE 2ML PER SYRINGE, which is used to treat hereditary angioedema. The delivery order has an April 2024 completion date and will support patient care programs across the VA's Veterans...
- The U.S. Department of Veterans Affairs (VA) awarded a firm fixed-price delivery order to Takeda Pharmaceuticals America Inc., a subsidiary of the global pharmaceutical company Takeda Pharmaceutical Company Limited, for the supply of the specialty medication TAKHZYRO (lanadelumab-flyo) 150mg/2mL injection. The $215,511.40 contract is part of the Pharmaceuticals and Drugs General Services Administration (GSA) Schedule 61-IB and will provide the critical treatment to VA medical facilities until...